search
Back to results

Haemoadsorption During Heart Transplantation (CytoSorbHTX)

Primary Purpose

Heart Transplantation

Status
Recruiting
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
CytoSorb Adsorber
Sponsored by
Medical University of Vienna
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Transplantation focused on measuring Heart Transplantation, Cytosorb

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients undergoing heart transplantation

Exclusion Criteria:

  • Declined informed consent
  • Age < 18 years#
  • Receiving antileukocyte drugs
  • Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)
  • DCD
  • Ex-vivo perfusion

Sites / Locations

  • Divison of Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University of ViennaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Adsorber Group

Control

Arm Description

Surgery with CPB will be performed according to institutional standards, depending on indications and surgical preferences. For the intervention group (adsorber-group), the CytoSorb adsorber will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 300-400 ml.min-1.

The control group (no-adsorber group) will be treated similarly, but no filter circuit will be installed.

Outcomes

Primary Outcome Measures

Difference in maximal cytokine peak levels (IL-1β, IL-6, IL-33, TNF-α, IL-10)
Difference in maximal cytokine peak levels in various cytokine levels compared to baseline measured by ELISA

Secondary Outcome Measures

Difference of immunosuppression (TTV)
Individual immunosuppression measured by Torque-teno-virus load
Difference of immunosuppression (sST2)
Individual immunosuppression measured by sST2 levels
primary graft dysfunction score
Differences in primary graft dysfunction score between both groups
30-day mortality
Differences in 30-day mortality between both groups
Mechanical Ventilation
Differences in length of mechanical ventilation
Delirium
Differences in Confusion assessment method for the ICU between both groups

Full Information

First Posted
February 2, 2022
Last Updated
March 13, 2023
Sponsor
Medical University of Vienna
search

1. Study Identification

Unique Protocol Identification Number
NCT05270902
Brief Title
Haemoadsorption During Heart Transplantation
Acronym
CytoSorbHTX
Official Title
Effect of Haemoadsorption During Cardiopulmonary Bypass on Patients After Heart Transplantation
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Vienna

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To investigate whether the use of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation (HTX) has an effect on circulating cytokine levels for the first 120 hours after HTX and induces a decreased inflammatory response, increased anti-inflammatory response or immunosuppressive response. Additionally, the influence of HA on primary graft dysfunction, postoperative cerebral dysfunction, postoperative fluid accumulation, renal dysfunction, duration of mechanical ventilation, length of ICU-stay and 30-day mortality should be investigated

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Transplantation
Keywords
Heart Transplantation, Cytosorb

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, single-center, single-blinded, randomized, controlled trial
Masking
Participant
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Adsorber Group
Arm Type
Active Comparator
Arm Description
Surgery with CPB will be performed according to institutional standards, depending on indications and surgical preferences. For the intervention group (adsorber-group), the CytoSorb adsorber will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 300-400 ml.min-1.
Arm Title
Control
Arm Type
No Intervention
Arm Description
The control group (no-adsorber group) will be treated similarly, but no filter circuit will be installed.
Intervention Type
Device
Intervention Name(s)
CytoSorb Adsorber
Intervention Description
Polymer based adsorber system for the elimination of cytokines
Primary Outcome Measure Information:
Title
Difference in maximal cytokine peak levels (IL-1β, IL-6, IL-33, TNF-α, IL-10)
Description
Difference in maximal cytokine peak levels in various cytokine levels compared to baseline measured by ELISA
Time Frame
5 days
Secondary Outcome Measure Information:
Title
Difference of immunosuppression (TTV)
Description
Individual immunosuppression measured by Torque-teno-virus load
Time Frame
30days
Title
Difference of immunosuppression (sST2)
Description
Individual immunosuppression measured by sST2 levels
Time Frame
30days
Title
primary graft dysfunction score
Description
Differences in primary graft dysfunction score between both groups
Time Frame
7 days
Title
30-day mortality
Description
Differences in 30-day mortality between both groups
Time Frame
30 days
Title
Mechanical Ventilation
Description
Differences in length of mechanical ventilation
Time Frame
up to 4 weeks
Title
Delirium
Description
Differences in Confusion assessment method for the ICU between both groups
Time Frame
5 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients undergoing heart transplantation Exclusion Criteria: Declined informed consent Age < 18 years# Receiving antileukocyte drugs Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab) DCD Ex-vivo perfusion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Martin H. Bernardi, MD, PhD
Phone
0043140400
Ext
41090
Email
martin.bernardi@meduniwien.ac.at
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin H. Bernardi, MD, PhD
Organizational Affiliation
Medical University of Vienna
Official's Role
Principal Investigator
Facility Information:
Facility Name
Divison of Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University of Vienna
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin H Bernardi, MD
Phone
004314040041090
Email
martin.bernardi@meduniwien.ac.at
First Name & Middle Initial & Last Name & Degree
Martin H Bernardi, MD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
after completion of study, the results will be published in a peer reviewed journal

Learn more about this trial

Haemoadsorption During Heart Transplantation

We'll reach out to this number within 24 hrs